Chemours (NYSE:CC) Rating Increased to Hold at Zacks Research

Chemours (NYSE:CC) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Thursday, Zacks reports.

A number of other research analysts have also recently weighed in on CC. The Goldman Sachs Group reiterated a “neutral” rating and issued a $17.00 target price on shares of Chemours in a report on Thursday, August 13th. BMO Capital Markets cut their price objective on Chemours from $26.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, August 13th. Alembic Global Advisors reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Chemours in a research note on Wednesday, May 13th. Morgan Stanley set a $18.00 target price on Chemours in a report on Monday, August 10th. Finally, Mizuho set a $22.00 target price on shares of Chemours in a research report on Wednesday, August 5th. Five investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Chemours has an average rating of “Hold” and a consensus price target of $20.10.

Chemours Stock Performance

NYSE:CC opened at $15.04 on Thursday. The company has a market cap of $2.26 billion, a P/E ratio of -7.88 and a beta of 1.42. The firm’s 50 day moving average is $16.39 and its two-hundred day moving average is $19.64. Chemours has a fifty-two week low of $10.44 and a fifty-two week high of $28.67. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98.

Chemours (NYSE:CC) last announced its quarterly earnings data on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.07). The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. Chemours had a negative net margin of 5.00% and a positive return on equity of 60.64%. The firm’s quarterly revenue was down 1.5% on a year-over-year basis. During the same period in the prior year, the firm earned ($2.54) earnings per share. Analysts expect that Chemours will post 0.87 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Denise Dignam bought 3,378 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was bought at an average price of $14.95 per share, for a total transaction of $50,501.10. Following the transaction, the chief executive officer owned 339,916 shares in the company, valued at $5,081,744.20. The trade was a 1.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Shane Hostetter bought 3,350 shares of the stock in a transaction on Thursday, August 6th. The shares were acquired at an average price of $14.94 per share, with a total value of $50,049.00. Following the purchase, the chief financial officer owned 102,698 shares of the company’s stock, valued at $1,534,308.12. The trade was a 3.37% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased a total of 8,663 shares of company stock valued at $130,601 in the last ninety days. Corporate insiders own 0.85% of the company’s stock.

Hedge Funds Weigh In On Chemours

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Chemours in the 2nd quarter valued at approximately $477,769,000. Cooper Creek Partners Management LLC acquired a new position in Chemours during the 3rd quarter worth $63,103,000. California State Teachers Retirement System grew its stake in shares of Chemours by 1,950.7% in the second quarter. California State Teachers Retirement System now owns 3,549,837 shares of the specialty chemicals company’s stock worth $72,843,000 after purchasing an additional 3,376,734 shares in the last quarter. Wolf Hill Capital Management LP bought a new position in shares of Chemours in the second quarter worth $59,698,056. Finally, Bank of New York Mellon Corp acquired a new position in shares of Chemours during the second quarter valued at $33,353,000. 76.26% of the stock is owned by institutional investors.

Chemours News Roundup

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours, DuPont and Corteva agreed to pay $455 million over 15 years to resolve claims brought by North Carolina and 11 local entities involving PFAS and other historical discharges from Chemours’ Fayetteville Works plant, as well as certain AFFF-related claims. Chemours’ share is approximately $180 million on a net-present-value basis, and the company said the obligation is covered by existing accruals, limiting the immediate earnings impact. Chemours, DuPont and Corteva Reach Agreement to Resolve PFAS-Related Claims in North Carolina
• Positive Sentiment: The settlement removes a significant portion of litigation uncertainty tied to the Fayetteville Works site and clarifies future cash obligations, which investors viewed favorably. Reports indicated Chemours shares rose during the session following the announcement. Why Is Chemours Stock Trading Higher Today?
• Neutral Sentiment: Several reports describe the agreement as a $380 million settlement with 11 public entities, while other headlines cite $590 million. These figures appear to reflect different components or descriptions of the broader resolution; the companies’ announced terms identify total settlement payments of $455 million over 15 years. Chemours, DuPont, Corteva settle North Carolina forever chemicals claims for $455 million
• Negative Sentiment: The agreement still represents a substantial long-term liability and does not eliminate broader PFAS-related regulatory, cleanup or litigation risks. Chemours’ results already show pressure from weaker revenue and an earnings miss, making continued legal-cost management important for investors.

About Chemours

The Chemours Company (NYSE: CC) is a global chemistry company headquartered in Wilmington, Delaware. Formed in 2015 through a spin-off from DuPont, Chemours develops and manufactures chemical products used in industries including transportation, electronics, energy, construction, and consumer goods.

The company operates through businesses focused on thermal and specialized solutions, titanium technologies, and advanced performance materials. Its products include refrigerants and heat-transfer fluids, titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper, as well as fluoropolymers, specialty fluids, and other performance materials used in demanding industrial applications.

Chemours serves customers in North America, Latin America, Europe, the Asia-Pacific region, and other international markets through manufacturing facilities, research and development operations, and commercial activities around the world.